½ÃÀ庸°í¼­
»óǰÄÚµå
1402481

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°

Asia Pacific Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 91 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº 2022³â 9,835¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 1¾ï 8,804¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 8.4%·Î ÃßÁ¤µË´Ï´Ù.

½ÉºÎ³úÀڱؿ¡¼­ ±â¼úÀÇ Áøº¸¿Í ½ÂÀÎÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀ» ÃËÁø

·Îº¿ À̽Ä, ´ÙÁß ´ë»ó ÀÚ±Ø, ¹Ì¼¼Àü±Ø ¼³°è °³¼±, ÃæÀü½Ä ÆÞ½º ¹ß»ý±â, °³º°È­µÈ ´ë»ó ÇÁ·Î±×·¡¹Ö µîÀº ³ú½ÉºÎÀÚ±ØÄ¡·á(DBS)ÀÇ ±â¼ú ¹ßÀü Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î DBS Àåºñ´Â ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í, ÆÄŲ½¼º´ ȯÀÚÀÇ È¿°ú¿Í Áõ»ó ¿ÏÈ­¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. AbbottÀÇ Infinity Deep Brain Stimulation SystemÀº ȯÀÚÀÇ Áõ»ó °ü¸®¸¦ µ½´Â »õ·Î¿î DBS ±â¼úÀÔ´Ï´Ù. 2020³â 2¿ù¿¡ ¹ßÇ¥µÈ MGM MedicalÀÇ º¸µµÀÚ·á¿¡ µû¸£¸é Ÿ¹Ð³ªµÎÀÇ MGM MedicalÀº °­¹ÚÀå¾Ö(OCD)¿¡ ´ëÇÑ Ã¹ ¹øÂ° ³ú½ÉºÎÀڱؿä¹ý Ä¡·áÁ¦·Î¼­, È¿À²ÀûÀÌ°í ¸ÂÃã Ä¡·á °ü¸®¸¦ Á¦°øÇÏ°í ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀÎ ÃÖÃÊÀÇ ¹«¼± iOS ¼ÒÇÁÆ®¿þ¾î DBS ¸ð¹ÙÀÏ Ç÷§ÆûÀÔ´Ï´Ù.¿¡ ´ëÇÑ ÃÖÃÊÀÇ ³ú½ÉºÎÀڱؿä¹ý(DBS)À» ½ÃÇàÇß½À´Ï´Ù. µû¶ó¼­ DBSÀÇ ±â¼ú ¹ßÀüÀº ¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉºÎ ³ú ÀÚ±Ø ½ÃÀå¿¡ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎÀÚ±ØÄ¡·á ½ÃÀå °³¿ä

Áß±¹Àº ¼¼°è¿¡¼­ °¡Àå ¸¹Àº ³ëÀÎ Àα¸¸¦ º¸À¯ÇÑ ±¹°¡·Î, The Lancet¿¡ °ÔÀçµÈ "China's Aging Population: Crisis or Opportunity?"(Áß±¹ÀÇ °í·ÉÈ­: À§±âÀΰ¡ ±âȸÀΰ¡?)¶ó´Â Á¦¸ñÀÇ ¿¬±¸ °á°ú¿¡ µû¸£¸é 2019³â¿¡ Áß±¹ÀÇ 60¼¼ ÀÌ»ó ³ëÀÎ Àα¸´Â 2¾ï 5400¸¸ ¸íÀ¸·Î, 2040³â¿¡´Â 4¾ï 200¸¸ ¸íÀ¸·Î Áõ°¡ÇÏ¿© Àüü Àα¸ÀÇ 28%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ºñ°¨¿°¼º ÁúȯÀÇ À§Çè°ú ºÎ´ãÀÌ Áõ°¡Çϰí ÀÇ·á »çȸº¸ÀåÁ¦µµ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϱ⠶§¹®¿¡ Áß±¹ÀÇ °øÁߺ¸°Ç¿¡ Áß´ëÇÑ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀÔ´Ï´Ù. ChinaDaily¿¡ µû¸£¸é 2023³â 2¿ù ÇöÀç Áß±¹¿¡´Â ¾à 400¸¸ ¸íÀÇ ÆÄŲ½¼º´ ȯÀÚ°¡ ÀÖÀ¸¸ç, 65¼¼ ÀÌ»ó Àα¸ÀÇ 1.7%°¡ ÆÄŲ½¼º´ Áø´ÜÀ» ¹Þ¾Ò´Ù°í ÇÕ´Ï´Ù. Population, and Nutrition Àú³Î¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é Áß±¹ÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ ȯÀÚ ¼ö´Â 600¸¸ ¸íÀ̸ç, 65¼¼, 75¼¼, 85¼¼ÀÇ Ä¡¸Å ºñÀ²Àº °¢°¢ 5%, 11.5%, 30%ÀÔ´Ï´Ù. ½Ã»ó ÇϺΠÇÙ(STN)ÀÇ ³ú ½ÉºÎ ÀÚ±Ø(DBS)Àº ÆÄŲ½¼ º´(PD) Ä¡·á¿¡ È¿°úÀûÀ̸ç, DBS Çϵå¿þ¾îÀÇ ¹ßÀü°ú ÇÔ²² ¿¬±¸ÀÚµéÀº ¸î °¡Áö »õ·Î¿î ÇÁ·Î±×·¡¹Ö ±â¼úÀ» °³¹ßÇßÀ¸¸ç, ±× Áß ¿ø°Ý ÇÁ·Î±×·¡¹ÖÀº Áß±¹¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Á¦Ç°(PINS Medical, Ltd., Áß±¹ º£ÀÌ¡)À» »ç¿ëÇÏ¿© ÆÄŲ½¼º´ ȯÀÚÀÇ ¿ø°Ý ÇÁ·Î±×·¡¹ÖÀ» ¼öÇàÇß½À´Ï´Ù. ÁøÇ༺ ÆÄŲ½¼º´ ȯÀÚ(15³â ÀÌ»óÀÇ ½Ã°£Àû ½Ã¾ß)¿¡°Ô DBS´Â ¸Å¿ì È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª DBS´Â ´Ù¸¥ ¼±Áø±¹°ú ´Þ¸® º¸ÇèÀÌ Àû¿ëµÇÁö ¾Ê´Â °æ¿ì ȯÀÚ¿¡°Ô Å« °æÁ¦Àû ºÎ´ãÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Áß±¹¿¡¼­´Â ¼ö¼ú ºñ¿ëÀº ÁַΠȯÀÚÀÇ °Ç°­ º¸Çè¿¡ ÀÇÇØ º¸ÀåµÇÁö¸¸ DBS Çϵå¿þ¾î ºñ¿ëÀº ºÎºÐÀûÀ¸·Î¸¸ º¸ÀåµÇ±â ¶§¹®¿¡ Áß±¹ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº ½Ì±Û ä³Î ½ÉºÎ³ú Àڱرâ, µà¾ó ä³Î ½ÉºÎ³ú Àڱرâ, ¼ÒÇÁÆ®¿þ¾î¿Í ¾×¼¼¼­¸®·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â µà¾ó ä³Î ½ÉºÎ³ú Àڱر⠺ι®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

¿ëµµº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº ÆÄŲ½¼º´, ÁøÀü, ±ÙÀ°±äÀåÀÌ»ó, °£Áú, ¾ËÃ÷ÇÏÀ̸Ӻ´, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â ÆÄŲ½¼º´ ºÐ¾ß°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº º´¿ø, ½Å°æ°úŬ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â º´¿ø ºÎ¹®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

±¹°¡º°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, Çѱ¹ , È£ÁÖ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â Áß±¹ ºÎ¹®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

Abbott Laboratories»ç, Beijing PINS Medical Co Ltd»ç, Boston Scientific Corp»ç, Medtronic Plc»ç, SceneRay Co Ltd´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : Áö¿ªº°

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ±¸µµ

  • ¼­·Ð
  • ¾Æ½Ã¾ÆÅÂÆò¾ç PEST ºÐ¼®
  • ºñ±³ ºÐ¼®
    • ³ú½ÉºÎ ÀÚ±ØÄ¡·á¿Í º´º¯ Çü¼º ½Ã¼úÀÇ ºñ±³
    • ½Å°æÁúȯ¿¡¼­ º´º¯ Çü¼º ÀýÂ÷
    • 2022³â¿¡ ½ÃÇàµÇ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ¼ö¼ú ½Ã¼ú : ±¹°¡º°

Á¦5Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ
    • ½Å°æÁúȯÀÇ À¯º´·ü »ó½Â
    • Àúħ½À¼ö¼úÀÇ ¼ö¿ä
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ³ú½ÉºÎ Àڱؿ¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë
  • ½ÃÀå ±âȸ
    • ³ú½ÉºÎ ÀÚ±ØÄ¡·á¿¡¼­ ±â¼úÀÇ Áøº¸¿Í ½ÂÀÎ
  • ÇâÈÄ µ¿Çâ
    • ¿¬±¸°³¹ßÀÇ È°¹ßÈ­
  • ¿µÇ⠺м®

Á¦6Àå ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ÆÇ¸Å°í, 2022-2030³â

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : Á¦Ç°º°

  • ¼­·Ð
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : Á¦Ç°º°, 2022³â¡¤2030³â ÆÇ¸Å°í Á¡À¯À²(%)
  • ½Ì±Û ä³Î ³ú½ÉºÎ ÀÚ±ØÄ¡·á
  • µà¾ó ä³Î ³ú½ÉºÎ ÀÚ±ØÄ¡·á
  • ¼ÒÇÁÆ®¿þ¾î¿Í ºÎ¼Óǰ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ¿ëµµº° ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø

  • ¼­·Ð
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ¿ëµµº°, 2022³â¡¤2030³â ÆÇ¸Å°í Á¡À¯À²(%)
  • ÆÄŲ½¼º´
  • ÁøÀü
  • ¾ËÃ÷ÇÏÀ̸Ӻ´
  • ±ÙÀ°±äÀåÀÌ»ó
  • °£Áú
  • ±âŸ

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø

  • ¼­·Ð
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2022³â¡¤2030³â ÆÇ¸Å°í Á¡À¯À²(%)
  • º´¿ø
  • ½Å°æ Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

  • °³¿ä
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ±¹°¡º° ¸®½ºÆ®
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦11Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ

  • COVID-19 ÀüÈÄÀÇ ¿µÇâ
  • °³¿ä

    Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¾÷°è »óȲ

    • ¼­·Ð
    • ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀÇ ¼ºÀå Àü·«
    • À¯±âÀû ¼ºÀå Àü·«
    • °³¿ä
    • ¹«±âÀû ¼ºÀå Àü·«
    • °³¿ä

    Á¦13Àå ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÁÖ¿ä ±â¾÷ °³¿ä

    • Abbott Laboratories
    • Medtronic Plc
    • Beijing PINS Medical Co Ltd
    • Boston Scientific Corp
    • SceneRay Co Ltd

    Á¦14Àå ºÎ·Ï

    KSA 24.01.16

    The Asia Pacific deep brain simulation market is expected to grow from US$ 98.35 million in 2022 to US$ 188.04 million by 2030. It is estimated to grow at a CAGR of 8.4% from 2022 to 2030.

    Technological Advancements and Approvals in Deep Brain Stimulation Drive Asia Pacific Deep Brain Simulation Market

    Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in deep brain stimulation (DBS). Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects. According to the MGM Healthcare press release published in February 2020, MGM Healthcare, Tamil Nadu, performed its first deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). Therefore, technological advancements in DBS are expected to create opportunities for the Asia Pacific deep brain stimulation market during the forecast period.

    Asia Pacific Deep Brain Simulation Market Overview

    China is home to the world's largest population of older adults. According to a study published in The Lancet titled "China's Aging Population: Crisis or Opportunity?" in 2019, people in China aged 60 or older were ~254 million. By 2040, that number is expected to rise to 402 million, ~28% of the population. These changes have profound public health implications in the country as the risk and burden of noncommunicable diseases increase along with the demand for health and social care systems. Parkinson's disease (PD) is a common neurodegenerative disease in the country. According to ChinaDaily, there were approximately 4 million Parkinson's patients in China as of February 2023, and ~1.7% of people over 65 years have been diagnosed with the disease. According to a study discussed in the Journal of Health, Population, and Nutrition, the number of people with Alzheimer's disease in China is ~6 million, with dementia rates among 65-, 75-, and 85-year-olds being 5%, 11.5%, and 30%, respectively. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in the treatment of Parkinson's disease (PD). With advancements in DBS hardware, researchers have developed several novel programming technologies, of which remote programming is widely used in China. Since 2018, we have been performing remote programming for patients suffering from PD using PINS products (PINS Medical, Ltd., Beijing, China). For patients with advanced Parkinson's disease (over a 15-year time horizon), DBS is considered to be a highly effective treatment option. However, DBS remains a significant economic burden on the patient when not reimbursed, unlike in any other developed country. In China, the surgery cost is mainly covered by the patient's health insurance, but the cost of DBS hardware is only partially covered, which can hamper the growth of the market in the country.

    Asia Pacific Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)

    Asia Pacific Deep Brain Simulation Market Segmentation

    The Asia Pacific deep brain simulation market is segmented into product, application, end user, and country.

    Based on product, the Asia Pacific deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Asia Pacific deep brain simulation market.

    Based on application, the Asia Pacific deep brain simulation market is segmented into Parkinson's disease, tremor, dystonia, epilepsy, Alzheimer's disease, and others. In 2022, the Parkinson's disease segment registered the largest share in the Asia Pacific deep brain simulation market.

    Based on end user, the Asia Pacific deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Asia Pacific deep brain simulation market.

    Based on country, the Asia Pacific deep brain simulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. In 2022, China segment registered the largest share in the Asia Pacific deep brain simulation market.

    Abbott Laboratories, Beijing PINS Medical Co Ltd, Boston Scientific Corp, Medtronic Plc, and SceneRay Co Ltd are some of the leading companies operating in the Asia Pacific deep brain simulation market.

    Reasons to Buy:

    • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific deep brain simulation market.
    • Highlights key business priorities in order to assist companies to realign their business strategies
    • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific deep brain simulation market, thereby allowing players across the value chain to develop effective long-term strategies
    • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
    • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the deep brain simulation market, as well as those hindering it
    • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

    Table Of Contents

    1. Introduction

    • 1.1 The Insight Partners Research Report Guidance
    • 1.2 Market Segmentation

    2. Executive Summary

    • 2.1 Key Insights
    • 2.2 Asia Pacific Deep Brain Stimulation Market, by Region (US$ Million)

    3. Research Methodology

    • 3.1 Coverage
    • 3.2 Secondary Research
    • 3.3 Primary Research

    4. Asia Pacific Deep Brain Simulation Market Landscape

    • 4.1 Overview
    • 4.2 Asia Pacific PEST Analysis
    • 4.3 Comparison Analysis
      • 4.3.1 Comparison of Deep Brain Stimulation and Lesioning Procedures
      • 4.3.2 Lesioning Procedures in Neurological Disorders
      • 4.3.3 Asia Pacific Deep Brain Stimulation Surgical Procedures Performed in 2022, By Country

    5. Asia Pacific Deep Brain Simulation Market - Key Industry Dynamics

    • 5.1 Key Market Drivers:
      • 5.1.1 Rising Prevalence of Neurological Disorders
      • 5.1.2 Demand for Minimally Invasive Surgery
    • 5.2 Market Restraints
      • 5.2.1 Side Effects Associated with Deep Brain Stimulation
    • 5.3 Market Opportunities
      • 5.3.1 Technological Advancements and Approvals in Deep Brain Stimulation
    • 5.4 Future Trends
      • 5.4.1 Growing Research and Development Activities
    • 5.5 Impact Analysis

    6. Deep Brain Simulation Market - Asia Pacific Market Analysis

    • 6.1 Asia Pacific Deep Brain Simulation Market Revenue (US$ Mn), 2022 - 2030

    7. Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Product

    • 7.1 Overview
    • 7.2 Asia Pacific Deep Brain Simulation Market Revenue Share, by Product 2022 & 2030 (%)
    • 7.3 Single Channel Deep Brain Stimulator
      • 7.3.1 Overview
      • 7.3.2 Single Channel Deep Brain Stimulator: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4 Dual Channel Deep Brain Stimulator
      • 7.4.1 Overview
      • 7.4.2 Dual Channel Deep Brain Stimulator: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.5 Software and Accessories
      • 7.5.1 Overview
      • 7.5.2 Software and Accessories: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)

    8. Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Application

    • 8.1 Overview
    • 8.2 Asia Pacific Deep Brain Simulation Market Revenue Share, by Application 2022 & 2030 (%)
    • 8.3 Parkinson's Disease
      • 8.3.1 Overview
      • 8.3.2 Parkinson's Disease: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.4 Tremor
      • 8.4.1 Overview
      • 8.4.2 Tremor: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.5 Alzheimer's Disease
      • 8.5.1 Overview
      • 8.5.2 Alzheimer's Disease: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.6 Dystonia
      • 8.6.1 Overview
      • 8.6.2 Dystonia: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.7 Epilepsy
      • 8.7.1 Overview
      • 8.7.2 Epilepsy: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.8 Others
      • 8.8.1 Overview
      • 8.8.2 Others: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)

    9. Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 - by End User

    • 9.1 Overview
    • 9.2 Asia Pacific Deep Brain Simulation Market Revenue Share, by End User 2022 & 2030 (%)
    • 9.3 Hospitals
      • 9.3.1 Overview
      • 9.3.2 Hospitals: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.4 Neurology Clinics
      • 9.4.1 Overview
      • 9.4.2 Neurology Clinics: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.5 Ambulatory Surgical Centers
      • 9.5.1 Overview
      • 9.5.2 Ambulatory Surgical Centers: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.6 Others
      • 9.6.1 Overview
      • 9.6.2 Others: Asia Pacific Deep Brain Simulation Market - Revenue and Forecast to 2030 (US$ Million)

    10. Asia Pacific Deep Brain Simulation Market - Country Analysis

    • 10.1 Overview
        • 10.1.1.1 Asia Pacific Deep Brain Simulation Market by Country
        • 10.1.1.2 China
          • 10.1.1.2.1 Overview
          • 10.1.1.2.2 China Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Mn)
          • 10.1.1.2.3 China Deep Brain Simulation Market, by Product
          • 10.1.1.2.4 China Deep Brain Simulation Market, by Application
          • 10.1.1.2.5 China Deep Brain Simulation Market, by End User
        • 10.1.1.3 Japan
          • 10.1.1.3.1 Overview
          • 10.1.1.3.2 Japan Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Mn)
          • 10.1.1.3.3 Japan Deep Brain Simulation Market, by Product
          • 10.1.1.3.4 Japan Deep Brain Simulation Market, by Application
          • 10.1.1.3.5 Japan Deep Brain Simulation Market, by End User
        • 10.1.1.4 India
          • 10.1.1.4.1 Overview
          • 10.1.1.4.2 India Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Mn)
          • 10.1.1.4.3 India Deep Brain Simulation Market, by Product
          • 10.1.1.4.4 India Deep Brain Simulation Market, by Application
          • 10.1.1.4.5 India Deep Brain Simulation Market, by End User
        • 10.1.1.5 Australia
          • 10.1.1.5.1 Overview
          • 10.1.1.5.2 Australia Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Mn)
          • 10.1.1.5.3 Australia Deep Brain Simulation Market, by Product
          • 10.1.1.5.4 Australia Deep Brain Simulation Market, by Application
          • 10.1.1.5.5 Australia Deep Brain Simulation Market, by End User
        • 10.1.1.6 South Korea
          • 10.1.1.6.1 Overview
          • 10.1.1.6.2 South Korea Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Mn)
          • 10.1.1.6.3 South Korea Deep Brain Simulation Market, by Product
          • 10.1.1.6.4 South Korea Deep Brain Simulation Market, by Application
          • 10.1.1.6.5 South Korea Deep Brain Simulation Market, by End User
        • 10.1.1.7 Rest of Asia Pacific
          • 10.1.1.7.1 Overview
          • 10.1.1.7.2 Rest of Asia Pacific Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Mn)
          • 10.1.1.7.3 Rest of Asia Pacific Deep Brain Simulation Market, by Product
          • 10.1.1.7.4 Rest of Asia Pacific Deep Brain Simulation Market, by Application
          • 10.1.1.7.5 Rest of Asia Pacific Deep Brain Simulation Market, by End User

    11. Pre & Post Covid-19 Impact

    • 11.1 Pre & Post Covid-19 Impact

    12. Asia Pacific Deep Brain Simulation Market Industry Landscape

    • 12.1 Overview
    • 12.2 Growth Strategies in Deep Brain Stimulation Market
    • 12.3 Organic Growth Strategies
      • 12.3.1 Overview
    • 12.4 Inorganic Growth Strategies
      • 12.4.1 Overview

    13. Deep Brain Simulation Market, Key Company Profiles

    • 13.1 Abbott Laboratories
      • 13.1.1 Key Facts
      • 13.1.2 Business Description
      • 13.1.3 Products and Services
      • 13.1.4 Financial Overview
      • 13.1.5 SWOT Analysis
      • 13.1.6 Key Developments
    • 13.2 Medtronic Plc
      • 13.2.1 Key Facts
      • 13.2.2 Business Description
      • 13.2.3 Products and Services
      • 13.2.4 Financial Overview
      • 13.2.5 SWOT Analysis
      • 13.2.6 Key Developments
    • 13.3 Beijing PINS Medical Co Ltd
      • 13.3.1 Key Facts
      • 13.3.2 Business Description
      • 13.3.3 Products and Services
      • 13.3.4 Financial Overview
      • 13.3.5 SWOT Analysis
      • 13.3.6 Key Developments
    • 13.4 Boston Scientific Corp
      • 13.4.1 Key Facts
      • 13.4.2 Business Description
      • 13.4.3 Products and Services
      • 13.4.4 Financial Overview
      • 13.4.5 SWOT Analysis
      • 13.4.6 Key Developments
    • 13.5 SceneRay Co Ltd
      • 13.5.1 Key Facts
      • 13.5.2 Business Description
      • 13.5.3 Products and Services
      • 13.5.4 Financial Overview
      • 13.5.5 SWOT Analysis
      • 13.5.6 Key Developments

    14. Appendix

    • 14.1 About Us
    • 14.2 Glossary of Terms
  • ºñ±³¸®½ºÆ®
    0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
    »óǰ ºñ±³Çϱâ
    Àüü»èÁ¦